Iceland· IS-IS/1/18/094/01

Gemcitabine WH

A gemcitabine product containing gemcitabinum inn hýdróklóríð, registered in Iceland by Williams & Halls ehf.*. The same ATC class is registered in 17 of our 19 countries.

ATC L01BC05

Checked against Icelandic Medicines Agency (Iceland) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about gemcitabinum inn hýdróklóríðAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Gemcitabine is registered in 17 of 19 countries.

Countries holding a registration under ATC L01BC05 (gemcitabine), each read from that country’s own register.

This record: Iceland, from Icelandic Medicines Agency (Iceland)
10 of them publish a price we can compare per daily dose

Search gemcitabine products by name

Gemcitabine · ATC L01BC05

17 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Franceprice
Germany
Icelandprice
Ireland
Netherlands
Norwayprice
Polandprice
Spainprice
Sweden
Switzerlandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of gemcitabine costs, country by country.

Normalised to the WHO defined daily dose (0.2 g), so markets compare like for like.

1 market with a comparable price for this class
Public list prices, converted to USD at the rate date shown

Open the full comparison — free account Drug prices for market access

Gemcitabine · price per daily dose (0.2 g)

USD · FX 28 Sept 2026

CH Switzerland$27.60

Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Icelandic Medicines Agency (Iceland)

Active substance: Gemcitabinum INN hýdróklóríð
Manufacturer: Williams & Halls ehf.*
Country: Iceland (IS)
ATC code: L01BC05
ATC class: Gemcitabine
Defined daily dose: 0.2 g, P
Reimbursed: Not published by this register
Source register: Icelandic Medicines Agency (Iceland)
Last checked: September 29, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

370 interactions on record for gemcitabine.

Graded by severity as the source publishes them — 33 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check gemcitabine against other medicines How interaction checks work

Gemcitabine · interactions on record

370 records

33 severe
114 moderate
19 minor
204 info

Most severe, free to view

MipomersenC10AX11severe
LomitapideC10AX12severe
CladribineL01BB04severe
PexidartinibL01EX15severe

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Gemcitabine in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All gemcitabine products

Authorised across Europe · EMA

The same active substance is authorised in 29 EEA countries. Names it is sold under:

Austria · Gemcitabin Accord, Gemcitabin Ebewe
Belgium · Gemcitabin Sandoz, Gemcitabin Sun
Bulgaria · Гемсол, Гемцитабин Акорд
Cyprus · Gemcitabine Accord, Gemnil
Czechia · Gemcitabin Ebewe, Gemcitabin Sun
Germany · Bendacitabin, Gemci-Cell
Denmark · Gemcitabin "sandoz", Gemcitabin Accord
Estonia · Gemcitabine Accord, Gemcitabine Kabi
Spain · Gemcitabina Accord, Gemcitabina Aurovitas Spain
Finland · Gemcitabin Accord, Gemcitabin Sandoz
France · Gemcitabine Accord, Gemcitabine Arrow
United Kingdom (Northern Ireland) · Gemcitabine Accord Healthcare, Gemcitabine Ennogen Ip
Greece · Demozar, Gemcipen
Croatia · Gemcitabin Accord, Gemcitabin Sandoz
Hungary · Gemcitabin Kabi, Gemcitabine Accord
Ireland · Gemcitabine, Gemcitabine Accord Healthcare
Italy · Gemcitabina Accord, Gemcitabina Aurobindo Pharma Italia
Lithuania · Gemcitabine Accord, Gemcitabine Kabi
Luxembourg · Gemcitabine Eg, Gemcitabine Eugia
Latvia · Gemcitabine Accord, Gemcitabine Kabi
Malta · Gemcitabine Pfizer Hellas, Gemnil
Netherlands · Gemcitabine Accord, Gemcitabine Fresenius Kabi
Norway · Gemcitabin Sandoz, Gemcitabin Sun
Poland · Gemcitabine Kabi, Gemcitabinum Accord
Portugal · Gemcit, Gemcitabina Accord
Romania · Gemcitabină Accord, Gemcitabina Kabi
Sweden · Gemcitabin Sandoz, Gemcitabin Sun
Slovenia · Gemcitabin Accord, Gemcitabin Kabi
Slovakia · Gemcitabín Sun, Gemcitabine Accord

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/3852d393-2a94-42e0-bbdb-85d26cf688a9
GET /v1/drugs/3852d393-2a94-42e0-bbdb-85d26cf688a9?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Innrennslisstofn, lausn",
  "source": "lyfjastofnun",
  "atc_raw": "L01BC05",
  "marketed": false,
  "strength": "200 mg",
  "ma_number": "IS/1/18/094/01",
  "substance": "Gemcitabinum INN hýdróklóríð",
  "other_info": null,
  "legal_status": "(R) Lyfseðilsskylt\r\n(H) Sjúkrahúsmerkt",
  "ma_issued_serial": "43332"
}

API reference MCP server Plans

See everything about gemcitabine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console